Vimarsana
Biggest News Aggregation in the World

Page 8 - Applied Testing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Applied Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Applied Testing Today - Breaking & Trending Today

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) - Vimarsana News

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

/PRNewswire/ -- Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion...

QIAGEN N.V.: QIAGEN Launches CE-marked Version of QuantiFERON SARS-CoV-2 to Assess T-cell Response to COVID-19 - Vimarsana News

QIAGEN N.V.: QIAGEN Launches CE-marked Version of QuantiFERON SARS-CoV-2 to Assess T-cell Response to COVID-19

Easy-to-use workflow can detect T-cell response early in the course of COVID-19 infection or following vaccination Detection of T-cells can provide vital insights that completes the picture

QIAGEN N.V.: QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON-TB Gold Plus assay on LIAISON XS - Vimarsana News

QIAGEN N.V.: QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON-TB Gold Plus assay on LIAISON XS

Additional U.S. approval for LIAISON XS platform builds on FDA approval in 2019 for QuantiFERON assay running on DiaSorin's LIAISON XL analyzer Collaboration now provides full range of automation

QIAGEN N.V.: QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529 - Vimarsana News

QIAGEN N.V.: QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence

QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529 - Vimarsana News

QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the